

**MICHAEL GIRARDI, MD**  
Associate Professor & Residency Director  
Department of Dermatology  
Yale University School of Medicine  
New Haven, Connecticut  
Tel. 203-785-6562 Fax.203-785-7234  
Email: michael.girardi@yale.edu



## EDUCATION

- 1988                    **B.S.** (Biology) & **B.A.** (Computer Science); Brown University, Providence, RI; *magna cum laude, Honors Thesis*
- 1992                    **M.D.**; Yale University School of Medicine, New Haven, CT; *Honors Thesis*

## ACADEMIC / HOSPITAL APPOINTMENTS

- 2006-present           Associate Clinical Director, Immunology & Immunotherapy Research Program  
Yale Comprehensive Cancer Center  
Yale-New Haven Hospital, New Haven, Connecticut
- 2004-present           Associate Professor of Dermatology  
Yale-New Haven Hospital, New Haven, Connecticut
- 2003-present           Co-Director, Photopheresis and Phototherapy Unit  
Yale-New Haven Hospital, New Haven, Connecticut
- 2004-present           Associate Professor, Department of Dermatology  
Yale University School of Medicine  
New Haven, Connecticut
- 2001-present           Residency Director, Department of Dermatology  
Yale University School of Medicine  
New Haven, Connecticut
- 1998-2004            Assistant Professor, Department of Dermatology  
Yale University School of Medicine  
New Haven, Connecticut
- 1997-present           Attending Physician, Department of Dermatology  
Yale-New Haven Hospital, New Haven, Connecticut
- 1997-2004            Attending Physician, Connecticut VA Medical Center  
West Haven, CT & Newington, CT

## POSTDOCTORAL TRAINING

- Internship:            Internal Medicine (1992-1993 )  
Yale-New Haven Hospital  
New Haven, Connecticut
- Research Fellow:     Laboratory of Robert Tigelaar, MD (1993-1994)  
Departments of Dermatology & Immunobiology  
Yale University School of Medicine  
New Haven, Connecticut

Residency                    Dermatology (1994-1997)  
Yale University School of Medicine  
New Haven, Connecticut

Research Fellow        Laboratory of Adrian Hayday, PhD (1996-1997)  
Departments of Biology & Immunobiology  
Yale University School of Medicine  
New Haven, Connecticut

#### **LICENSURE AND CERTIFICATION**

1990                    National Boards of Medical Examiners, Step 1  
1992                    National Boards of Medical Examiners, Step 2  
1993                    National Boards of Medical Examiners, Step 3  
1997                    American Board of Dermatology  
2005                    American Board of Dermatology, Recertification Certificate

#### **HOSPITAL COMMITTEE ASSIGNMENTS**

2001                    Graduate Medical Education, Internal Review Committee  
2005-present        Med-Mentors Program (Career advice program for medical students)

#### **MEMBERSHIPS IN PROFESSIONAL SOCIETIES**

2006-Pres.        Member of the Board, Member of Medical and Scientific Committee, Dermatology  
Foundation  
2006-Pres.        Member, Dermatology Teachers Exchange Group  
2005-Pres.        Member, Medical Dermatology Society  
2003-Pres.        Member, Association of Professor in Dermatology  
2003-2005        Vice Chair for Connecticut, Dermatology Foundation  
1999-2003        Leaders Society, Dermatology Foundation  
1997-Pres.        Fellow, American Academy of Dermatology  
1996                Member, New York Academy of Science  
1995-Pres.        Member, Society of Investigative Dermatology  
1992                Member, American Medical Association  
1988                Member, Sigma Xi Scientific Research Society  
1998                Member, American Association for Cancer Research

#### **NATIONAL STUDY SECTIONS**

2006-Pres.        Dermatology Foundation Study Section  
2006                NIH Clinical Program Project – Special Emphasis Panel  
2004                NIH TTT Study Section

#### **NATIONAL APPOINTMENTS / SELECTIONS**

2006-2009        SID, Committee on Scientific Programs

2005 AAD Synergy Summit  
 2004 AAD Solutions Summit  
 2004 AAD Leadership Program  
 2004 Cutaneous Lymphoma Masters  
 2004-Pres. International Society for Cutaneous Lymphoma  
 2006-Pres. Board Member, Dermatology Foundation  
 NIH / SID Residents' Retreat

### **JOURNAL EDITORIAL ACTIVITY**

Journal of Investigative Dermatology (Associate Editor)  
 DermClips, American Academy of Dermatology (Editorial Board)  
 Archives of Dermatology (Reviewer)  
 Carcinogenesis (Reviewer)  
 Immunology (Reviewer)  
 Journal of Clinical Investigation (Reviewer)  
 New England Journal of Medicine (Reviewer)

### **HONORS & PROFESSIONAL RECOGNITION**

1988 Member, Sigma Xi Scientific Research Society  
 1988 Sigma Xi, Scientific Research Society selection, Brown University, Providence, RI  
 1988 Harvey A. Baker Fellowship Award: "Excellence in Academia  
 Extracurricular Activities, and Community Service," Brown University, Providence, RI  
 1988 David Beinecke Award: "Excellence in the Academic Sciences," Brown University, RI  
 1988 Big Brothers of Rhode Island, Outstanding Service Award, Providence, RI  
 1990 Farr Scholar Award for "Leadership, integrity, and intellectual honesty"  
 Yale University School of Medicine, New Haven, CT  
 1992 Farr Scholar Award (Repeat Recipient), Yale University School of Medicine  
 1992 Transplantation Research Award, Yale University School of Medicine  
 1992-Pres. Member, American Medical Association  
 1995-Pres. Member, Society of Investigative Dermatology  
 1996 Member, New York Academy of Science  
 1996 Almay Inc. Research Award, Dermatology Foundation, Chicago, IL  
 1997 Lila Gruber Cancer Research Award, American Academy of Dermatology, Chicago, IL  
 1997-Pres. Fellow, American Academy of Dermatology  
 1998 Member, American Association for Cancer Research  
 1999-2003 Leaders Society, Dermatology Foundation  
 2000 Swebilius Research Award, Skin Cancer Research Award  
 2002 American Skin Association Award, Skin Cancer Research  
 2002-present Member, International Society of Cutaneous Lymphoma

2003-2006 Vice Chair for Connecticut, Dermatology Foundation  
 2005 Reviewer, NIH study section: Transplantation, Tolerance, and Tumor Immunology  
 2006-present Medical and Scientific Committee, Annenberg Circle, Dermatology Foundation  
 2006-present Committee on Scientific Programs, Society of Investigative Dermatology  
 2007 Reviewer, NCI study section: SPORE Grants  
 2007-present Associate Editor, *Journal of Investigative Dermatology*

## GRANT HISTORY

### Current Support

National Institutes of Health/National Cancer Institute 1 RO1 CA102703-01  
 T Cell Regulation of Cutaneous Malignancy Project period: 7/1/03-6/30/08  
 Principal Investigator: Michael Girardi, M.D. % effort: 50%  
 Total grant amount: \$1,818,940 Total/year: \$363,788 Direct cost/year: \$222,500

National Institutes of Health/NIAMSD 1 R01 AR049282-01A1  
 Regulation of Cutaneous Inflammation by Local  $\gamma\delta$  T Cells Project period: 9/1/03-7/31/08  
 Principal Investigator: Robert Tigelaar, M.D. % effort: 10%  
 Total grant amount: \$1,785,911 Total /year: \$380,797 Direct cost/year: \$235,000

National Institutes of Health/National Cancer Institute 2 P30 CA16359-02  
 Yale Comprehensive Cancer Center, Immunology & Immunotherapy Program  
 Principal Investigator: Richard Edelson, M.D. Project period: 8/9/07-7/31/08  
 % effort: 2.50%  
 Total grant amount: \$9,355,000 Total/year: \$1,871,000 Direct cost/year: \$1,133,653

Connecticut Department of Public Health BCH-2005-920  
 Phase I Toxicity/Feasibility Study: Combined Modality Treatment with Transimmunization and  
 Radiation for Non-Small Cell Lung Cancer  
 Principal Investigator: Lynn Wilson, M.D. Project period: 5/1/05-6/30/07  
 % effort: 1%  
 Total grant amount: \$350,000 Total/year: \$350,000 Direct cost/year: \$304,348

National Institutes of Health/National Cancer Institute 1 P50 CA121974-02  
 Yale SPORE in Skin Cancer  
 Developmental Research Project- (7/1/06 – 6/30/08) Mechanism(s) of immunotolerance mediated by  
 extracorporeal photopheresis in cutaneous T-cell lymphoma (CTCL) patients treated prophylactically  
 or therapeutically to ameliorate GVHD.  
 Principal Investigator: Ruth Halaban, Ph.D. Project period: 7/1/06-6/30/11  
 % effort: 3%  
 Total grant amount: \$11,233,194 Total/year: \$2,233,300 Direct cost/year: \$1,353,515

Career Development Award Program  
 Analysis of Tumor-Promoting T Cells Project period: 7/1/06-6/30/08  
 Principal Investigator: Michael Girardi, M.D. % effort: 5%  
 Total grant amount: \$172,634 Total/year: \$86,182 Direct cost/year: \$65,043

Yale Cancer Center Clinical Immunology Grant  
 Immunotherapy & Immunology Program  
 CTLA-4 Blockade for Cutaneous T Cell Lymphoma Project period: 7/1/06-6/30/07  
 Principal Investigator: Michael Girardi, M.D. % effort: 5%

Total grant amount: \$30,000                      Total/year: \$30,000                      Direct cost/year: \$30,000

**Prior Support**

Coley Pharmaceutical Group, Inc. (1 CPG7909-CO14)  
A Phase I/II Open Label, Multi-Center Study for the Evaluation of CpG 7909 in Patients with Stage IB to IVA Cutaneous T-Cell Lymphoma                      Project period: 12/18/02-11/19/05  
Principal Investigator: Michael Girardi, M.D.                      % effort: 0%  
Total grant amount: \$77,513                      Total/year: \$38,756                      Direct cost/year: \$29,813

Coley Pharmaceutical Group, Inc. (1 CPG7909-CO16)  
A Continuation Study of CpG 7909 in Patients with Metastatic or Recurrent Malignancies who have Stable Disease or who have responded to Therapy for their Malignancies and have Completed a Previous Study of CpG 7909 as a Single Agent or in Combination with Another Anti-Neoplastic Therapy.                      Project period: 11/1/03-10/7/05  
Principal Investigator: Michael Girardi, M.D.                      % effort: 0%  
Total grant amount: \$77,513                      Total/year: \$38,756                      Direct cost/year: \$29,813

Genmab, Inc. (Hx-CD4-110)  
HuMax-CD4 in Refractory Mycosis Fungoides: A Double Blind, Randomized, Parallel Group, Multi-Center Clinical Trail of HuMax-CD4, a Fully Human Monoclonal Anti-CD4 Antibody, in Patients with Mycosis Fungoides type CTCL (stage 1B-IVB) who are Refractory or Intolerant to Targretin (bexarotene) and one other Standard Therapy  
Principal Investigator: Michael Girardi, M.D.                      Project period: 10/5/04-10/7/05  
% effort: 0%  
Total grant amount: \$39,204                      Total/year: \$39,204                      Direct cost/year: \$30,434

Yale-New Haven Hospital/Yale University                      New Clinical Program Development Fund  
Transimmunization                      Project period: 7/1/01-6/30/04  
Principal Investigator: Michael Girardi, M.D.                      % effort: 20%  
Total grant amount: \$671,200                      Total/year: \$249,894                      Direct cost/year: \$249,894

National Institutes of Health/NIAMSD                      5 K08 AR02072-05  
TCR DNA Immunization for 2B4.11 T Cell Lymphoma                      Project period: 7/30/98-6/30/03  
Principal Investigator: Michael Girardi, M.D.                      % effort: 80%  
Total grant amount: \$584,242                      Total/year: \$126,090                      Direct cost/year: \$116,750

American Skin Association                      Career Development Research Grant  
The Immuno-evolution of SCC Development                      Project period: 7/1/02-6/30/03  
Principal Investigator: Michael Girardi, M.D.                      % effort: n/a  
Total grant amount: \$50,000                      Total/year: \$50,000                      Direct cost/year: \$50,000

Yale Comprehensive Cancer Center                      Swebelius Award  
Immunobiology of Murine PDV Squamous Cell Carcinoma                      Project period: 4/1/99-3/31/00  
Principal Investigator: Michael Girardi, M.D.                      % effort: 10%  
Total grant amount: \$25,000                      Total/year: \$25,000                      Direct cost/year: \$25,000

American Association for Cancer Research                      Fellowship Grant  
Immunization for T-Cell Lymphoma                      Project period: 7/1/97-6/30/98  
Principal Investigator: Michael Girardi, M.D.                      % effort: 80%  
Total grant amount: \$30,000                      Total/year: \$30,000                      Direct cost/year: \$30,000

Dermatology Foundation                      Research Grant

DNA Vaccination Against Murine T Cell Lymphoma	Project period: 7/1/97-6/30/98
Principal Investigator: Michael Girardi, M.D.	% effort: 10%
Total grant amount: \$10,000	Direct cost/year: \$10,000

Dermatology Foundation	Fellowship Grant
Cutaneous Immunology in V $\gamma$ 5 DETC deficient mice	Project period: 7/1/96-6/30/97
Principal Investigator: Michael Girardi, M.D.	% effort: 80%
Total grant amount: \$25,000	Direct cost/year: \$25,000

National Institutes of Health/NIAMSD (Training Grant)	5 T32 AR07016
Principal Investigator: Richard Edelson, M.D.	Project period: 7/1/93-6/30/96
Total grant (current): \$1,329,297	% effort: 25%
Individual Recipient: \$75,000	Direct cost/year: \$263,050
Total/year: \$282,899	Direct cost/year: \$28,500

### National Lectures, Courses:

- 2008 *University of Utah, Department of Dermatology, Grand Rounds, "Cutaneous T Cell Lymphoma: Pathogenesis and Therapy Update", Chicago, IL (Scheduled: Dec 5, 2008)*
- 2008 *British Society of Immunology, Plenary Talk, "Local Immunoregulation of Epithelial Transformation", Glasgow, Scotland (Scheduled: Nov. 14, 2008)*
- 2008 *Joint Meeting of the European Society for Dermatological Research (ESDR), Japanese Society for Investigative Dermatology (JSID), Society for Investigative Dermatology (SID), "Rapid Reorganization of Local Immune Components by NKG2D Ligand Expression", Kyoto, Japan (Scheduled: May 14, 2008)*
- 2008 *Memorial Sloan-Kettering Cancer Center, "Extracorporeal Photoimmunotherapy in GVHD", New York, NY (Scheduled: June 5, 2008)*
- 2007 *Yale School of Medicine, 2<sup>nd</sup> Annual Scientific Symposium on Nephrogenic Systemic Fibrosis and MRI Contrast, CME Conference, "Clinical Spectrum of Definition of NSF" New Haven, CT (Scheduled: May 10, 2008)*
- 2008 *Northwestern University, Dermatology Grand Rounds, "Photopheresis in the management of CTCL and GVHD"; Basic Science Seminar, "Immunoregulation of Cutaneous Malignancy", Chicago, IL (Scheduled: May 7, 2008)*
- 2008 *University of Minnesota, Keynote Speaker, Research Day, "Local Immune Regulation of Cutaneous Malignancy", Minneapolis, MN (Scheduled: April 25, 2008)*
- 2008 *H. Lee Moffitt Cancer Center & Research Institute, "Strategies for GVHD Treatment and Prevention", Tampa, FL (Feb. 26, 2008)*
- 2008 *American Academy of Dermatology, Symposium, "Cutaneous Lymphoma Update 2008", San Antonio, TX (Feb. 4, 2008)*
- 2008 *American Academy of Dermatology, Advanced Immunology Course, "Tumor Immunology", San Antonio, TX (Feb. 4, 2008)*
- 2007 *Boston University, Department of Dermatology, "Clinical Spectrum of Nephrogenic Systemic Fibrosis", Boston, MA (Dec. 5, 2007)*
- 2007 *Montagna Symposium on Epidermal T Cell Interactions, "Local Immunoregulation of Carcinogenesis" Gleneden Beach, OR (Oct. 12, 2007)*

- 2007 *Yale School of Medicine*, 1<sup>st</sup> Annual Scientific Symposium on Nephrogenic Systemic Fibrosis and MRI Contrast, "A Dermatologist's Perspective on NSF" New Haven, CT (May 4, 2007)
- 2007 *King's College, Department of Immunobiology*, "Inflammation and Carcinogenesis: Turmoil in the Skin" London (Mar. 2, 2007)
- 2007 *St. John's Institute of Dermatology*, "Anti- and Pro-Tumor Responses in the Skin" London (Feb. 28, 2007)
- 2007 *American Academy of Dermatology*, Course, "Tumor Immunology" Washington D.C. (Feb. 1, 2007)
- 2007 *American Academy of Dermatology*, Symposium, "Cutaneous T Cell Lymphoma" Washington D.C. (Feb. 1, 2007)
- 2007 Center for Drug Evaluation and Research, Division of Training and Development, "Cutaneous Manifestations of Nephrogenic Systemic Fibrosis" Bethesda, MD (Jan. 31, 2007)
- 2006 *University of California, Los Angeles*, Dermatology Grand Rounds Invited Speaker, "Cancer Immunosurveillance: Shifting the Balance" Los Angeles, CA (Oct. 31, 2006)
- 2006 *Society of Investigative Dermatology*, Concurrent Minisymposium, "Decreased carcinogenesis in Langerhans cell-deficient mice" Philadelphia, PA (May 4, 2006)
- 2006 *Society of Investigative Dermatology*, Concurrent Minisymposium, "Chronic inflammation-driven tumor promotion associated with interferon- $\gamma$ -producing, perforin-defective CD8+ T cells" Philadelphia, PA (May 5, 2006)
- 2006 *NIH Workshop in Immunology and Immunobiology of CTCL* and *Society of Investigative Dermatology*, Concurrent Minisymposium, "Transimmunization for cutaneous T cell lymphoma: A phase I study." Philadelphia, PA (May 6 and 7, 2006)
- 2006 *American Academy of Dermatology*, Symposium, "Management of Cutaneous T Cell Lymphoma." San Francisco, CA (Mar. 3, 2006)
- 2006 *American Academy of Dermatology*, Course, "Tumor Immunology." San Francisco, CA (Mar. 6, 2006)
- 2006 *American Academy of Dermatology*, Symposium, "Fundamental Immunology for the Practicing Dermatologist", Invited Lecture for the Basic Review Course, San Francisco, CA (Mar. 4, 2006)
- 2006 *Kings College*, "Examining the Unconventional T Cell Response in Mouse Models of Cancer" , Invited Lecture, London/Windsor, UK (Feb. 20, 2006)
- 2005 *Society of Investigative Dermatology*, Concurrent Minisymposium, "Cutaneous malignancy susceptibility in NKG2D-ligand transgenic mice." St. Louis, MO (May 7, 2005)
- 2005 *American Academy of Dermatology*, Symposium, "Management of Cutaneous T Cell Lymphoma." Washington, DC (Feb. 22, 2005)
- 2004 *Society of Investigative Dermatology*, Concurrent Minisymposium, "V $\gamma$ 5+ dendritic epidermal T cells are required for optimal regulation of cutaneous inflammation and protection of the epidermal barrier." Providence, RI (May 1, 2004)
- 2004 *Robert Wood Johnson University Hospital*, Oncology Grand Rounds, "Update on Therapy of the Cutaneous Lymphomas." New Brunswick, NJ (Mar. 10, 2004)

- 2004 *National Jewish Medical and Research Center*, Conference on  $\gamma\delta$  T cells, "Distinct contributions of  $\alpha\beta$  and  $\gamma\delta$  T cells to cutaneous malignancy." Denver, CO (to be given, Mar. 6, 2004)
- 2004 *American Academy of Dermatology*, Symposium, "Modern Therapeutics in Dermatology: Cutaneous T Cell Lymphoma." Washington, DC (to be given: Feb. 6, 2004)
- 2004 *American Academy of Dermatology*, Focus Session, "Update on Cutaneous T Cell Lymphoma." Washington, DC (to be given Feb. 8, 2004)
- 2003 *Brigham & Women's Hospital/Harvard University*, Department of Dermatology, Invited Research Seminar, "T Cell Regulation of Cutaneous Malignancy." Boston, MA (Feb. 7, 2003)
- 2003 *American Academy of Dermatology*, Focus Session, "Cutaneous T Cell Lymphoma," San Francisco, CA (Mar. 22, 2002).
- 2003 *Society of Investigative Dermatology*, "Characterizing the Inhibition of Transplantable Squamous Cell Carcinoma Growth by  $\alpha\beta$  T Cells," Miami Beach, FA (May 3, 2003)
- 2002 *National Cancer Institute*, Mouse Models of Human Cancer Consortium (MMHCC), Invited Lecture, "Distinct Roles for  $\alpha\beta$  and  $\gamma\delta$  T Cells in Cutaneous Carcinogenesis." Boston, MA (June 26, 2002)
- 2002 *Society of Investigative Dermatology*, Oral Presentation, "Defective epidermal barrier function in  $\gamma\delta$  T cell deficient mice." Los Angeles, CA (May 18, 2002).
- 2002 *American Academy of Dermatology*, Focus Session, "Understanding Cutaneous T Cell Lymphoma: Clinical Spectrum and Novel Therapeutic Approaches," New Orleans, LA (Feb. 22, 2002).
- 2001 *International Conference on Technology in Cancer Research and Treatment in the New Millenium* (Adenine Press), Invited Lecture, "Large Scale Dendritic Cell Loading with Apoptotic Tumor Cell Antigens," Albany, NY (June 30, 2001)
- 2001 *Society of Investigative Dermatology*, Oral Presentation, "Anti-Tumor and Tumor-Promoting Capacities of  $\alpha\beta$  and  $\gamma\delta$  T Cells on Cutaneous SCC Development is Dependent on Mode of Carcinogenesis," Washington, DC (May 12, 2001).
- 2001 *University of California at San Francisco, Zion Cancer Center*, Invited Lecture, "Understanding How Different Sets of T Cells Regulate the Development of SCC," (March 9, 2001)
- 2001 *American Academy of Dermatology*, Symposium: CTCL Clues, Pitfalls, and Strategies, "CTCL Treatment: Cure vs. Control," Washington, DC (March 4, 2001).
- 2000 *Wake Forest University*, Department of Dermatology, Invited Lecture, "T Cell Subset Regulation of Cutaneous Inflammation and Carcinogenesis," Winston-Salem, NC (Sep. 14, 2000)
- 2000 *Southern Medical Association*, Invited Lecture, "General Immunology Review through the Eyes of a Dermatologist," Orlando, FL (Nov. 4, 2000)
- 2000 *Young Leaders in Dermatology Conference*, "Cutaneous Lupus: Diagnosis and Treatment," Scottsdale, AZ (Nov. 1, 2000)
- 2000 *Society of Investigative Dermatology*, Oral Presentation, "Analysis of the  $\alpha\beta$  T Cell Immune Response to Murine PDV Squamous Cell Carcinoma," Chicago, IL
- 2000 *Society of Investigative Dermatology*, Oral Presentation, "Optimal Anti-Tumor Immunity to Murine Squamous Cell Carcinoma is Dependent on Both CD4 and CD8 T Cell Responses," Chicago, IL
- 2000 *Guy's/St. Thomas Hospital*, Invited Lecture, "The Adaptive Immune Response to Murine Squamous Cell Carcinoma," London, UK

## BIBIOGRAPHY

### 1. Peer-Reviewed Manuscripts

- Girardi M**, Herreid P, Tigelaar R. Specific suppression of lupus-like graft versus host disease using extracorporeal photochemical attenuation of effector lymphocytes. *J Invest Dermatol*. 1995, 104:177-182.
- Girardi M**/ Dudley E (dual first authorship), Owen M, and Hayday A.  $\alpha\beta$  and  $\gamma\delta$  T cells can share a late common precursor. *Curr Biol*. 1995, 5:659-669.
- Girardi M**, Oppenheim D, Lewis J, Filler R, Tigelaar RE, Hayday AC. The regulation of squamous cell carcinoma development by  $\gamma\delta$  T cells. *Science*. 2001, 294:605-609.
- Berger CL, Longley J, Hanlon D, **Girardi M**, Edelson R. The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma. *Annals NY Acad Sci*. 2001, 941:106-122.
- Girardi M**, Lewis J, Glusac E, Filler RB, Geng L, Hayday AC, Tigelaar RE. Resident skin-specific  $\gamma\delta$  T cells provide local regulation of cutaneous inflammation. *J Exp Med*. 2002, 195:855-867.
- Girardi M**, Glusac E, Filler R, Tigelaar R, Hayday A. The distinct contributions of murine TCR $\alpha\beta^+$  and TCR $\gamma\delta^+$  T cells to different stages of chemically-induced skin cancer. *J Exp Med*. 2003, 198:747-755.
- Gao Y, Yang W, Pan M, Scully E, **Girardi M**, Augenlicht LH, Craft J, Yin Z. Gamma delta T cells provide an early source of interferon gamma in tumor immunity. *J Exp Med*. 2003, 198:433-442.
- Girardi M**, Sherling MA, Filler R, Shires J, Theodoridis E, Hayday AC, Tigelaar RE. Anti-inflammatory effects in the skin of thymosin- $\beta$ 4 splice-variants. *Immunol*. 2003,109:1-7.
- Girardi M**, Oppenheim D, Lewis J, Filler R, Tigelaar RE, Hayday AC. Characterizing the protective component of the  $\alpha\beta$  T cell response to transplantable squamous cell carcinoma. *J Invest Dermatol*. 2004, 122:699-706.
- Oppenheim D, Roberts S, Clarke S, Filler R, Lewis J, Tigelaar R, **Girardi M**, Hayday A. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. *Nat Immunol*. 2005, 9:928-937.
- Girardi M**, Berger C, Wilson L, Christensen I, Thompson K, Glusac E, Edelson R. Transimmunization for cutaneous T cell lymphoma: a Phase I study. *Leukemia and Lymphoma*. 2006, 47:1495-1503.
- Girardi M**, Lewis J, Filler R, Hayday A, Tigelaar R. Environmentally responsive and reversible regulation of epidermal barrier function by gamma/delta T cells. *Journal of Invest Derm*. 2006, 26:808-814.
- Lewis J, **Girardi M**, Roberts S, Barbee S, Hayday A, Tigelaar R. Selection of the cutaneous intraepithelial  $\gamma\delta^+$  T cell repertoire by a thymic stromal determinant. *Nat Immunol*. 2006, 7:843-850.
- Wakabayashi Y, Mao J, Brown K, **Girardi M**, Balmain A. Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the *Patched* gene in FVB mice. *Nature*. 2007, 445:761-765.
- Roberts SJ, Ng BY, Filler RB, Lewis J, Glusac EJ, Hayday AC, Tigelaar RE, **Girardi M**. Characterizing tumor-promoting T cells in chemically induced cutaneous carcinogenesis. *Proc Natl Acad Sci U S A*. 2007,104:6770-6775.
- Kuo PH, McClennan BL, Carlson K, Wilson LD, Edelson RL, Heald PW, **Girardi M**. FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma. *Mol Imaging Biol*. 2008, 10:74-81.

Kuo PH, Carlson KR, Christensen I, **Girardi M**, Heald PW. FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a Phase II Trial. *Mol Imaging Biol*. 2008, 10:306-314.

Boyden LM, Lewis JM, Barbee SD, Bas A, **Girardi M**, Hayday AC, Tigelaar RE, Lifton RP. Skint1, the prototype of a newly identified immunoglobulin superfamily gene cluster, positively selects epidermal gammadelta T cells. *Nat Genet*. 2008, 40:656-662.

Strid J, Roberts SJ, Filler RB, Kwong BY, Schpero W, Kaplan DH, Hayday AC, **Girardi M**. Acute upregulation of an NKG2D-ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. *Nat Immunol*. 2008, 9:146-154.

## **2. Case Reports, Technical Notes, Letters**

**Girardi M**, Federman G, McNiff JM. Familial multiple basaloid follicular hamartomas: a report of two affected sisters. *Ped Dermatol*. 1999, 16:281-284.

**Girardi M**, Glusac E, Imaeda S. Subcutaneous Fusarium foot abscess in a renal transplant patient. *Cutis*. 1999, 63:267-270.

**Girardi M**, Berger C, Hanlon D, Edelson RL. Efficient tumor antigen loading of dendritic antigen presenting cells by transimmunization. *Tech Cancer Res Treatment*. 2002, 1:65-69.

Schaffer JV, Carroll C, Dvoretzky I, **Girardi M**. Post-irradiation morphea of the breast: Presentation of two cases and review of the literature. *Dermatol*. 2002, 200:67-71.

**Girardi M**, Duncan K, Tigelaar R, Imaeda S, Watsky K, McNiff J. Cross-comparison of patch test and lymphocyte proliferation responses in patients with a history of acute generalized exanthematous pustulosis. *Amer J Dermatopath*. 2005, 27:343-346.

Reyes CM, Rudinskaya A, Kloss R, **Girardi M**, Lazova R. Scleroderma-like illness as a presenting feature of multiple myeloma and amyloidosis. *J Clin Rheumatol*. 2008, 14:161-165.

## **3. Reviews, Chapters, Books**

Hoffman E, Dudley E, **Girardi M**, Hayday A. "The  $\alpha\beta/\gamma\delta$  lineage decision: An evaluation of the 'T cell determinant,' 'progenitor precommitment,' or co-determinant' models" in *Molecular Biology of B-cell and T-Cell Development*. Monroe, J, Rothenberg, E (eds.) Humana Press, Inc., 1998.

**Girardi M**, Heald PW. Cutaneous T cell lymphoma and cutaneous graft-versus-host disease: Two Indications for Photopheresis in Dermatology. *Dermatol*, 2000.

**Girardi M**, Edelson R. Cutaneous T cell lymphoma. *Oncology*. 2000,14:1061-1070.

Schaffer JV, **Girardi M**. "Morphea" in *Emedicine Online Textbook*, 2000; [www.emedicine.com](http://www.emedicine.com).

Schaffer JV, **Girardi M**. "Bullous lupus" in *Emedicine Online Textbook* 2000; [www.emedicine.com](http://www.emedicine.com).

Knobler R. **Girardi M**. Extracorporeal photochemoimmunotherapy in cutaneous T cell lymphomas. *Annals NY Acad Sci*. 2001, 941:123-138.

**Girardi M**, Heald PW. "Extracorporeal photochemotherapy" in *Comprehensive Dermatologic Drug Therapy*, S. Wolvertin (ed). W.B. Saunders, Philadelphia, 2001, pp. 326-338.

**Girardi M**, Schechner J, Glusac E, Berger C, and Edelson R. Transimmunization and the evolution of extracorporeal photochemotherapy. *Transfus Apher Sci*. 2002, 26:181-190.

Berger CL, Hanlon D, Kanada D, **Girardi M**, Edelson RL. Transimmunization, a novel approach for tumor immunotherapy. *Transfus Apher Sci*. 2002, 26: 205-216.

Taraszka K, **Girardi M**. Treatment of cutaneous T cell lymphoma: Advances in understanding disease behavior and implications for management. *Yearbook Dermatol Dermatol Surg*. 2003, 18:1-26.

**Girardi M**, Knobler R, Edelson R. Selective immunotherapy through extracorporeal photochemotherapy: Yesterday, today, and tomorrow. *Hematology/Oncology Clin*. 2003, 17:1391-403.

- Girardi M**, Heald P, Wilson L. Medical Progress: The pathogenesis of mycosis fungoides. *New Eng J Med*. 2004, 350:1978-1988.
- Girardi M**. Cutaneous biology of gamma/delta T cells. *Adv Dermatol*. 2004, 20:203-215.
- Berger C, Mariwalla K, **Girardi M**, Edelson R. Advances in understanding the immunobiology and immunotherapy of cutaneous T-cell lymphoma. *Adv Dermatol*. 2004, 20:217-235.
- Girardi M**, Hastings KT. Update on Cutaneous T-Cell Lymphoma: Pathogenesis and Therapy. *DermQuest Thought Leader Commentary: Research Update 2005*, [www.dermquest.com](http://www.dermquest.com).
- Hayday A, **Girardi M**. Mechanisms of epithelial defense: immunosurveillance by gamma/delta T cells. *Chem Immunol and Allerg*. 2005, 86:136-150.
- Wilson L, Jones G, **Girardi M**, Edelson R, Heald P. "Cutaneous T cell lymphoma" in *Cancer: Principles and Practice of Oncology*, DeVita, Hellman, Rosenberg (eds.) 7th Ed; Philadelphia: Lippincott Williams & Wilkins, 2005, pp. 1998-2011.
- Taraszk K, Glusac E, Wilson L, **Girardi M**. "Mycosis fungoides and Sézary syndrome: Pathophysiology and Pthology" in *The Lymphoid Neoplasms*. Magrath I (ed). 3<sup>rd</sup> Edition, Hodder Arnold, London, 2005, pp. 201-216
- Girardi M**. The therapeutic potential of extracorporeal photopheresis. *Clin Adv Hematol Oncol*. 2006, 4:349-350.
- Girardi M**. Immunosurveillance and immunoregulation by gammadelta T cells. *J Invest Dermatol*. 2006, 126:25-31.
- Girardi M**, Heald PW. "Extracorporeal Photochemotherapy" in *Comprehensive Dermatologic Drug Therapy*, S. Wolvertin, (ed), 2<sup>nd</sup> Ed. W.B. Saunders, Philadelphia, 2007, pp. 326-338.
- Filler R, Roberts S, **Girardi M**. Cutaneous two-stage chemical carcinogenesis. *CSH Protocols*; doi:10.1101/pdb.prot4837, 2007.
- Girardi M**. Cutaneous perspectives on adaptive immunity. *Clinic Rev Allergy Immunol*. 2007, 33: 4 - 14.
- Callen J, Chamlin S, Eichenfield L, Ellis C, **Girardi M**, Goldfarb M, Hanifin J, Lee P, Margolis D, Paller AS, Piacquadio D, Peterson W, Kaulback K, Fennerty M, Wintroub BU. A systematic review of the safety of topical therapies for atopic dermatitis. *Brit J Dermatol*. 2007,156:203-221.
- Cowper SE, Rabach M, **Girardi M**. Clinical and histological findings in nephrogenic systemic fibrosis. *Eur J Radiol*. 2008, 66:191-199.
- Girardi M**. Nephrogenic Systemic Fibrosis: A Dermatologist's Perspective. *J Am Coll Radiol*. 2008, :40- 44.
- Girardi M**. "Conventional and Unconventional T Cells" in Gaspari, Tying (Eds.) *Clin Immunoderm*. Springer, 2008.

#### **4. Guidelines and Consensus Statements**

- ISCL/EORTC. "Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)." *Blood*. 2007,110:1713-1722.
- ISCL/EORTC. "TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous

Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC).”*Blood*. 2007,110:479-484.

#### **5. Papers in Press**

Craiglow B, Hinds G, Antaya R, **Girardi M**. Primary cutaneous aspergillosis in an immunocompetent patient: successful treatment with oral voriconazole. *Pediatric Dermatol*.

Neustadter J, Samarin F, Carlson K, **Girardi M**. Extracorporeal photochemotherapy for generalized deep morphea. *Arch Dermatol*.